Q-omics provides the consensus-scored ZBTB7C profile across patient tissues and cancer cell-line models. ZBTB7C expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZBTB7C is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, ZBTB7C RNA expression shows 20,380 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where ZBTB7C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB7C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB7C survival associations across molecular data types. ZBTB7C RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB7C RNA expression–survival associations across cancer types. High ZBTB7C expression shows unfavorable associations in ACC and UVM, but favorable associations in HNSC, COAD, MESO and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZBTB7C RNA expression.
This table summarizes ZBTB7C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB7C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB7C shows lower tumor expression in COAD, HNSC, KICH, KIRC, LUAD and KIRP. The COAD box plot shows higher ZBTB7C RNA expression in normal versus tumor tissue (log2 FC = −2.478, t-test p < 0.001).
This table shows molecular features associated with ZBTB7C in patient tissues and cancer cell lines. In patient samples, ZBTB7C shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB7C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LUNG_SCLC.
